Sanofi

News and Events

Press Releases


February 3, 2026
Press Release: Sanofi announces the signing of a share buyback mandate for up to €1 billion

February 2, 2026
Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease

January 30, 2026
Press Release: Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease

Upcoming Events

23Apr

2026

First Quarter 2026

First quarter 2026 results will be reviewed by management during a live audio webcast with the financial community on April 23, 2026. The presentation will be followed by a Q&A session.

Quarterly results


30Jul

2026

Second Quarter 2026

Second quarter 2026 results will be reviewed by management during a live audio webcast with the financial community on July 30, 2026. The presentation will be followed by a Q&A session.

Quarterly results


30Oct

2026

Third Quarter 2026

Third quarter 2026 results will be reviewed by management during a live audio webcast with the financial community on October 30, 2026. The presentation will be followed by a Q&A session.

Quarterly results


Past Events

29Jan

2026

Fourth Quarter & Full Year 2025 Results

Fourth quarter and full year 2025 results were reviewed by management during a live audio webcast with the financial community on January 29, 2026. The presentation was followed by a Q&A session.

14:30 - 16:00 CET (8:30am – 10am EDT)

Quarterly results

Discover more

24Oct

2025

Third Quarter 2025

Third quarter 2025 results were reviewed by management during a live audio webcast with the financial community on October 24, 2025. The presentation was followed by a Q&A session.

Quarterly results

Discover more

31Jul

2025

Second Quarter 2025

Second quarter 2025 results were reviewed by management during a live audio webcast with the financial community on July 31, 2025. The presentation was followed by a Q&A session.

Quarterly results

Discover more